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tween thev ery-low-density-lipoproteinr eceptor andt -PAa nd t-PA:PAI-1c omplexesi na dditiont ot hosep reviouslyd escribed with low-density-lipoproteinreceptor-related protein. Moreover, t-PA:PAI-2 bound to both endocytosisreceptors with similarkinetics to t-PA.These differential biochemical interactions between t-PAa nd thet -PA:PAI complexesmay underlie theobserved differences in endocytosismechanisms on thePBMs. This suggests that while PAI-1and PAI-2function similarlyinthe controlofcellularplasmingenerationbyt-PA, they may havedisparateeffects on thealternative functions of t-PAvia modulation of itsengagement with endocytosisreceptors.
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Introduction
Thet issue (t-PA) and urokinase (u-PA) plasminogen activators convertplasminogentoplasmin, whichisinvolvedinfibrinolysis, tissue remodellingand cell migration.u-PAisassociatedwithproteolysis withinthe pericellular environment; whilst the role of t-PA has beencoupledwithfibrinolysis (1) . More recent reportssuggest thatt -PAi sn ot restricted to maintaining homeostasis of coagulation and fibrinolysis. Forexample,t-PAhas beenshown to playa role in angiogenesis and neurobiology viacellsurface interactions with annexinII(p36), the annexinIIheterotetramer(AIIt) (comprisedoftwo subunits of p36and twoofp11) and the low-densitylipoprotein-receptor-related protein (LRP) (2) (3) (4) . Furthermore, cellso fm yeloid lineagei nterchangeablye xpress t-PA, u-PAa nd their specific inhibitorsspecificallyduringactivation or differentiation processes (5) (6) , thought he physiologicali mplicationso f thisrequiresfurtherinvestigation.
t-PAi sa72 kDa glycosylated protein,w hichi ss ecretedi na singlechain form (sc-t-PA) by peripheralblood monocytes(7) and endothelial cells ( 8) . Cleavageo fs c-t-PA produces the 62.9 kDa twoc hain (tc) t-PA conformation (9) . Both sc-t-PAa nd tc-t-PA displaye nzymatic activity towards plasminogen,w hichi se nhanced when theyare bound to fibrin (10) . In addition to fibrininteractions, both formsoft-PAalsobind, vialysinedependent interactions, to monocyte,macrophage,endothelial andhuman tumourc elll ines and efficientlya ctivatec ell-boundp lasminogen (11) (12) (13) (14) .
Controlofplasmingeneration by sc-t-PAortc-t-PA in vivo is thought to be mediated predominantlyt hrought he inhibitory functionso ft he plasminogena ctivator inhibitor type 1( PAI-1/SERPINE1)and potentiallytoalesserextentbyplasminogenactivator inhibitor type 2( PAI-2/SERPINB2) ( 15) . As memberso f the serine protease inhibitor (serpin)family,PAI-1 andP AI-2 exhibit as uicides ubstrate-like inhibitorym echanism viat he formation of a1 :1 covalentlyl inked, serpin-proteasec omplex (16) (17) . Both PAI-1 and PAI-2 efficientlyi nhibit tc-t-PAi ns olution phasew iths econdo rder rate constants of~10 7 and 10 5 M -1 .s -1 ,r espectively,a nd both arei nefficienti nhibitorso ff ibrin bound t-PA (18, 19) . Thereforet-PA:PAI complexesare typically formed aftert-PAdissociatesfromthe fibrinclot. However, PAI-1 is consideredthe primary inhibitor of t-PAasitisabletoformserpin-proteasec omplexesw ithb oth sc-t-PAa nd tc-t-PAa nd is found in normal humanplasma at concentrationsrangingfrom 140 pM to 1.9n M ( 20) . PAI-2 does not interact with sc-t-PAi n plasma and is only detected during latestage pregnancy(20) but, with concentrationsreachingapproximately200 ng.mL -1 (4 nM), PAI-2 has beenproposedtoplayarole in maintaining placental integrity by moderating excessive fibrinolysis in normal pregnancy (21) . Despite this, little is understood aboutthe role of PAI-2 as a physiologicalinhibitor of t-PAdue to limitedreports of t-PA:PAI-2 complexesi dentified in vivo (1) . Ye t, co-expressiono ft -PAa nd PAI-2 has beenshown in normal bone marrow (5), skin (22) , saliva andsalivaryglandtissue (23) , gingival fluid (24) (25) , as well duringpregnancy (21) , and PAI-2 is able to inhibit cell surfacebound tc-t-PA in vitro (13) . Furthermore, enhanced expression of both t-PAand PAI-2 by epithelial cellsisindicative of some inflammatory disease states, such as periodontal disease (24) and psoriasis (1), strongly suggestingarole forPAI-2 in the controloft-PAactivityatsites of localisedinflammation.This is furthersupported by the finding that PAI-2 butnot PAI-1 is relativelyr esistant to oxidativeconditionswhichare symptomaticofinflammation (26) .
Whilst PAI-2 expression canbeup-regulated by avariety of cell typesunder stress conditions, the predominant physiologicalproducers of PAI-2 aremonocytes and macrophages (1) . Monocytes alsoexpress and secretet-PA(7) whichhas beenshown to bind to the surfaceofthese cellsvia numerous and variedreceptors (11, 12, 27) . Furthermore, Ritchie et al. (28) reported the up-regulation of PAI-2 expression by monocytescultured in the presence of thrombin. This suggests apotential role forPAI-2 in the homeostatic balance between thrombosis and fibrinolysis at localsites of inflammation or during wound healing processes,possibly through the inhibition and clearanceoftc-t-PA from the pericellular environment.
Clearanceoft-PAand t-PA:PAI-1 from the circulation viaendocyticp rocesses in the liveri sw ellc haracterised ( 29, 30) . The mechanismsfor endocytosis of these ligands have beenshown to be dependent on membersofthe low-density-lipoprotein receptor (LDLR) family, specifically LRP (31, 32) and scavenger receptors such as the mannosereceptor(CD206) (27) . Therateofendocytosis of PAI-1-inhibited t-PAwas shown to be acceleratedcompared to t-PAonly, on rathepatomacells (31) . This acceleration in clearancewas found to be duetothe increasedaffinityoft -PA:PAI-1 complexesf or LRP ( 32) . Interestingly, Camani et al. (33) found that Novikoff rathepatomacells,MEF-1 mouseembryonic fibroblasts,HT1080 fibroblasts and COS Africangreen monkey kidney cellsw erea ll able to degrade[ 125 I]t-PAa nd [ 125 I]t-PA:PAI-1 via LRP-mediated uptake, whilst the THP-1 and U-937monocytic cell lines were not.The authors suggested that aco-receptor, absent on the THP-1 and U-937celllines, mayberequiredfor these ligands to interact with LDLRs. However, t-PAwas shown to specifically bind to the surfaceoffreshly isolated peripheralblood monocytes (PBM),T HP-1 andU -937 cell lines (11) . Macrophages derived from humanPBMs were shown to takeupand degrade[ 125 I]t-PA viat he mannoser eceptor ( 12) . Furthermore, Simone ta l. (34) showedLDLR-familydependent endocytosis and degradation of [ 125 I]t-PA:PAI-1 by the THP-1 cell line. Thus,the potentialfunction of PAI-1 or PAI-2 in the inhibition and enhanced endocytosis of t-PAboundtomyeloid cell typesremains unclear.
In the presentstudy,weaimed to clarify and comparethe role of these serpinsasregulatorsofcellular t-PAand the fateoft-PA:serpininhibitorycomplexes. Freshly isolated PBMs were utilisedasa non-transformed t-PA-dependent cellular modelr epresenting myeloid lineages (5) .These were profiled forknown t-PAreceptors as well as endocytosis receptorsa ssociatedw ithp rotease:serpin complexcellsurface clearance, such as LRPand the very-low-density-lipoprotein receptor (VLDLR). In addition,asthe interactions of t-PA:PAI-2 with LRP, or t-PAa nd t-PA:PAI complexesw ith VLDLR hadnot previously beenstudied, surfaceplasmonresonance(SPR) wasusedtocomparethe binding kinetics of allthree ligands to both these receptors.
Methods

Materials
Recombinant humanPAI-2 (47 kDa form)was providedbyPAI-2 PtyL td (Sydney, Australia).P urifiedh uman receptor associated protein (RAP),r ecombinant humanP AI-1 (stable mutant) and humantc-t-PA were obtainedfromMolecular Innovations(Novi, MI, USA). SpectrozymeP Ls ubstrate,m urinea nti-humanu -PA B-chain IgG 1 (#394), murine anti-humant -PAI gG 1 (#E-4) and murine anti-humanLRP α-chain IgG 1 (#3402) were supplied by AmericanD iagnostica Inc. (Stamford, CT,U SA). Rabbita ntihumanVLDLR IgGa nd rabbita nti-annexinI I( p36) were from SantaCruzBiotechnology, Inc. (Santa Cruz,CA, USA).Goatanti-S100A10 (p11) was from R&D Systems(Indianapolis, IN, USA). Goat anti-rabbitFITCconjugate IgG(whole molecule), goat antimouse IgG( Fabs pecific) FITCc onjugate,r abbita nti-goat IgG (whole molecule) FITCc onjugate,g oatI gG, propidiumi odide (PI),H anks balanceds alt modifieda nd non-modified, bovine seruma lbumin( BSA), humanf ibrin, D-phenylalanyl-L-prolyl-L-arginine chloromethyl keytone(PPACK) andOptiPrep densityg radientm edium were from Sigma-Aldrich( St. Louis, MO, USA). Alexa4 88 protein labelling kita nd Alexa4 88 quenching polyclonal antibodyw eref romM olecular Probes (Eugene, OR, USA). Murine α-CD14-texas redc onjugatedm onoclonala ntibodywas purchased from Invitrogen (Carlsbad, CA, USA). Murine α-CD206 monoclonal antibodywas purchased from Hycult-biotech (Uden, TheN etherlands). Recombinant humant-PA(Actylise, amixture of sc and tc-t-PA) was akindgift from BoehringerIngelheim (North Ryde, NSW,Australia).
Leeetal. t-PAand t-PA:PAI-1 versus t-PA:PAI-2 interactions with LRP andVLDLR
Isolationofhuman PBMs
Peripheralv enous blood was collectedf romd onorsi ntoE DTA vacuum tubes (BDB iosciences, NorthR yde, NSW,A ustralia) under controlled conditionsbyatrainedphlebotomist at the Universityo fW ollongong( UOW) (protocol approved by UOW, HumanE thics Committee,a pproval number HE00/221). Buffy coats were prepared by centrifuging whole blood samples at 1,300 gfor 30 minutes(min).Whiteblood cellswereremoved understerileconditionsand monocytesisolated usingOptiPrep as perthe manufacturer's instructions. This methodology yieldedcellpreparationscontaining 60 to 80% CD14 positive(monocyte)cells as determined by flow cytometry. Freshly isolated PBMs were used immediatelyfor allexperiments.
Plasminogenactivationassays
Cellswerewashedand resuspendedat1x10 6 cells.mL -1 in Tr is Buffered Saline(TBS)(50 mM Tr is, 150 mM NaCl,pH7.4), incubated on iceinthe absenceorpresenceof100 nM t-PAfor 40 minand thenwashedtwice in TBS to remove excess unbound protein.Triplicate 50 µlc ells uspensionsw eret hena liquoted into 96-well microtitre plates and incubatedfor 15 minatroomtemperature,in the absenceo rp resenceo fi ncreasingc oncentrationso fP AI-1, PAI-2 and 10 µg.mL -1 plasminogenmadeuptoafinal volume of 100 µlw ithT BS buffer.S pectrozyme PL substrate (100 µl) was then added to afinal concentration of 0.25 mM and substrate conversionbyplasminmeasuredkineticallyat405 nm over 2hours at 37°CusingaSpectraMax 250 platereader; datawas recorded using SoftMax  Pros oftware( Molecular Devices). Negative controls contained cellsa lone (not -PAo rp lasminogen).O therc ontrols consisted of t-PA(100 nM)inthe absenceorpresenceof1.4 µMfi-brin,plasminogen(10 µg.mL -1 )and SpectrozymePL(0.25 mM), as previously described (13) . Backgroundabsorbance(buffer only wells) was subtracted from alldata.
Flow cytometry analysis
Cell surfaceantigendetection
Membrane bound antigens were detected usingindirect immunofluorescence assays,e ssentiallya sp reviouslyd escribed (35) . Briefly,c ells were suspendeda taf inal concentration of 1x10 6 cells.mL -1 in icecold binding buffer (phenol red-freeHanks buffered salt solution,pH7.4,containing 1mMCaCl 2 ,1mM MgCl 2 and 0.1% BSA) containing 10 µg.mL -1 of primaryantibodyand incubatedonice for40min.After washingsteps,the cellswereresuspended with ice-cold binding buffer containing 1:100 dilution of FITC-conjugateds econdarya ntibody, followed by incubation with 10 µg.mL -1 α-CD14-texas redc onjugateda ntibody( for identification of PBMs).Cells were thenwashedprior to analysis by flow cytometry, with viable cell populationss electedt hrough propidiumi odide (PI) exclusion.I sotype matchedc ontrol antibodies were used to assess non-specificbinding duetothe primary antibody. Alld ata obtainedw as analysed usingF LOJO software version7.1 (Treestar, Inc, Ashland, OR, USA) and was restricted to CD14-positive/PI-negative cells. Allgeometric mean fluorescence valuesreportedrepresent mean fluorescence intensityfor specific binding ±SEM. Allassays were conductedintriplicate.
Protein binding assays
Cell surfacebinding analyses were conductedbyincubatingcells on icei nb inding buffer containing increasinga mountso f Alexa488-labelledt-PA(t-PA Alexa488 )orBSA (BSA Alexa488 )(negative control) for40min.This wasdoneinorder to allowmaximalcell surfacebinding by alsominimisinginternalisation of t-PA. Cells were thenwashedtwice with icecold PBS andanalysed usingflow cytometryasdescribed above.
Internalisationassays
These were conducteda sp reviouslyd escribed (36) . Briefly,cells were incubatedf or 40 mina t1 x10 6 cells.mL -1 in binding buffer, containing 0( control) or 100 nM t-PAo rt -PA Alexa488 ,o ni ce to minimise internalisation.After washingtoremoveexcess unbound t-PA, cellswereincubated with eitherPAI-2 or PAI-2 Alexa488 (where stated) , PAI-1 or no additionsand incubatedat37°Cfor the time periodsi ndicated. Alls ubsequents teps were performeda t4°C. Thecells were next washed twiceand incubatedfor 30 minwith4 µg.mL -1 alexa488 quenchinga ntibody( quenches anyr emaining cell surfacefluorescence and is thus ameasure of internalisedligand).Then, afterwashing,the cellswereincubated for40min with 10 µg.mL -1 α-CD14monoclonalantibody. Finally, the cellswere washed twicewithice cold PBS andanalysed usingflowcytometry as described above.
Surface plasmon resonance assays
Kinetic analysis was performedusingaBIAcore 2000 (BIAcoreAB, Uppsala,Sweden).LRP or VLDLR was immobilisedontoaCM5 BIAcore chip accordingtothe manufacturer's instructions. Briefly, the chip was activated usinga1:1m ixture of 0.2MN -ethyl-N'-(3-dimethylaminopropyl)carbodi-imide and 0.05 M N-hydroxysuccimide. LRPorVLDLR was coated on to the chip at 40 µg.mL -1 in 10 mM sodium acetateb uffer (pH3 )f or 7m in at 5 µl.min -1 ,aspreviouslydescribed (37) , to alevel of 2,000 response units (VLDLR)or2,000 to 10,000 response units (LRP). Theunoccupied binding sites were blockedusing1Methanolamine,pH 8.5. Analytes (t-PA,t-PA:PAI) were buffer exchanged into running buffer (10 mM HEPES (pH7 .4), 140 mM NaCl,1mM CaCl 2 , 0.05% v/v Tween-20) before applying to the BIAcore chip at 20 µl.min -1 .Aserial dilution of analytes rangingfrom500 -15nM were used to allowkineticanalyses. t-PA:PAI complexeswereprepared by incubating t-PAw ithP AI-1 (1:1m olar ratio) or PAI-2 (1:3molar ratio) for60min at 37°C. An excess of PAI-2 could be used and not removedfromthe t-PA:PAI-2 solutionsasun-reacted PAI-2 does not bind LRPorVLDLR (36) (37) (38) . Non-reducingSDS-PAGE confirmedthe presenceoft -PA:PAI-1 or t-PA:PAI-2 complexeswithm inimal/negligibler esidual free t-PAo rP AI-1 (data not shown). In allcases the analyteconcentration referstothe concentration of t-PApresent.Regeneration of the chip was achieved using100 mM H 3 PSO 4 .All bufferswerefilteredand degassedbefore use. Forkineticanalysis, ablankcellwas used as the reference cell and data was analysed usingBIAevaluation software(Ve rsion 3). 
Statistical analysis
Results
To assess basalendogenous cell surfaceexpressionlevelsofp lasminogenactivatorsand endocytosis receptorsofthe LDLR family, immunofluorescence assays of PBMs were undertaken usingflow cytometry. ThePBMs expressedrelativelylow levels of u-PAand t-PA( Ta ble1 ). LRPa nd VLDLR were alsod etectedo nP BMs ( Table 1) . We next investigated cell surfaceexpressionofthe mannosereceptorand AIIt (sub-units p36and p11), both knowncell surfacereceptors fort-PA (12, 40) . Whilst p36was expressedonthe PBMs, neitherthe mannosereceptornor p11weredetectable on these cells(Ta ble1).
Sinceatleast oneknown t-PAr eceptor, p36, was detected, we tested the binding of exogenous t-PAtoPBMs.Whenincubated on icet om inimise internalisation and/orp roteolytic activity,t he binding of t-PAt oP BMs wass aturable within4 0m in,showing maximum binding at about200 nM ( Fig.1A) .Anegative control BSA Alexa488 didnot bind to the cell surfaceatthe highest equivalent t-PA concentration (Fig.1B) .Wenexttested the contribution of LDLRstothe direct binding of t-PAtoPBMs.Pre-incubation of the cellswithRAP,acommonlyusedantagonist of ligand binding specific to the LDLR family, significantly reducedcellsurface bindingofexogenous t-PAtoPBMs by 30% (Fig.1C) .This levelofinhibitionwas consistentwithprevious studies usinghuman umbilicalv ein endothelial cells ( 39) , indicating that LDLR family membersare functional cell surfacereceptors fort-PAinaddition to the potentiallyn umerous other receptorsr epresented by the non-RAP inhibitable binding interactions. Furthermore, t-PA bound only to the CD14-positivestained(i.e. PBM) cellswithin the cell suspension, indicating that the otherblood cell typespresentd id not bind measurable (and therefore didn ot internalise) amountsoft-PA (Fig.1D) .
Saturation of the cell surfacewithexogenous t-PAcaused asignificant increase in cellular plasminactivity ( Fig.2) , whichwas only four-foldslowerthant-PAmediated plasminogenactivation in the presence of fibrin(ΔO.D.min -1 =0.012 ±0.0001 SEM).The very lowlevelsofintrinsic plasmin generation in the absenceofexogenous t-PAconfirmedthe lowexpressionofcellsurface t-PA(or u-PA) as determined by immunofluorescence assays ( Table 1) . As expected from previous work showing inhibition of cell surface t-PAbyP AI-2 on the MCF-7 and HeLa cell lines (13), PAI-2 was alsoabletoinhibit cell surfacet-PAonPBMs at similar concentrations (Fig.2) . PAI-1 wasoverall more efficientatinhibitingplasminf ormation compared to PAI-2, resultingi n9 5-100% inhibitiona ta ll concentrationsu sed ( Fig.2 ) . However, at 50 nM PAI-2 inhibited about80% of plasminformation whileat200 nM both serpinsinhibited plasminformation by >90%.
Thefateofactiveand inactivated t-PAonPBMs wasnextexamined. Freshly isolated PBMs were found to endocytose t-PAinthe absenceorpresenceofeitherserpin ( Fig.3) . However, PAI-1 significantly enhanced the proportion of t-PAinternalisedfromthe cell surfaceafter 20 minand 30 minincubationswhilst PAI-2 did not (Fig.3) . This differential effectont-PAendocytosis by the serpins was surprisingasPAI-2 haspreviouslybeenshown to enhance the uptakeofu-PAfromthe surfaceofprostatecancer cells, albeit not to the same extent as PAI-1 (37) .
To ensure that PAI-2 not only inhibited (i.e. bound) to cell surface t-PAbut was itself subsequentlyendocytosed as at-PA:PAI-2 ©Schattauer 2010
Thrombosisand Haemostasis 104.6/2010 complex, internalisation assays usingP AI-2 Alexa488 andexogenous active-t-PAorPPACK-inactivated t-PAwereperformed. Cell surface bound PPACK-inactivated t-PAsignificantly reducedthe internalisation of PAI-2 by 90% ( Fig.4) , indicating that the majorityofP AI-2 bound at the PBMcellsurface was subsequentlyendocytosedasat-PA:PAI-2 complex. Thiswas alsosupported by the inabilityofPAI-2 to be internalisedbycells not pre-incubatedwith exogenous t-PA(datanot shown), whichagain confirmedthatthe levels of endogenous t-PA(or u-PA) on the PBMs were very low. In order to confirmthatendocytosis receptorsare involved in the clearanceoft-PAand t-PA:PAI complexesfromthe PBMcell surface, the rolesofscavenger receptorsand the LDLR familywere investigated. RAPsignificantly inhibited t-PA:PAI complexinternalisation by 80-90% in allc ases ( Fig.5 ) . Fucoidin,w hichi s known to blockscavenger receptors, inhibited only 10-20% of the internalisation (Fig.5) . This indicatesthatreceptors of the LDLR familyplayamajorrole in clearing t-PAand t-PA:PAI complexes from the PBMcellsurface,while scavenger receptorsplayonlya minorrole in thisprocess. Previous studies identifiedthe mannose receptor (CD206) as at-PAclearance receptor on livercells (40) and expression of thisreceptorhas beenreportedfor primarymacrophages (12) . However, as PBMs didnot expressdetectable levels of the mannosereceptor(Ta ble1), it is unlikely that thisreceptor plays ar ole in the fucoidin-inhibitable clearanceo ft -PAo r t-PA:PAI complexesbythese cells. Theidentityofthe fucoidin-inhibitablereceptors that mediateaminorfraction of the clearance of t-PAand t-PA:PAI complexesfromthe surfaceofPBMs remains unclear.
Leeetal. t-PAand t-PA:PAI-1 versus t-PA:PAI-2 interactions with LRP andVLDLR
Sincethe most likely endocytosis receptorsonthe PBMs were LRPand VLDLR (asascertainedbycellprofiling; refer to Ta ble1), the kinetics of binding of t-PAand t-PA:PAI complexestoimmobilisedLRP and VLDLR were analysed usingsurface plasmon resonance(SPR).Initial specificityanalyses usingoverlay plots of sensogramsindicatedthatt-PA:PAI-1 bound more strongly to LRPthan t-PA alone or in complexwithP AI-2 ( Fig. 6A ). This effect was lessobvious with VLDLR ( Fig.6B) .For kineticanalyses aserialdilution of ligands were used,whichrevealeddosedependent bindingfor allofthe analytes (data not shown)and complexbinding interactionsoft-PA:PAI-1 to both LRPand VLDLR.Nevertheless, in both cases,the databest fit competitive heterogeneous analyte models,suggestingthe presenceofarelativelylow-and ahigh-affinitybinding sitewithin the complexfor both LRP(K D1 ∼21.2nM, K D2 ∼0.95 nM,respectively)and VLDLR (K D1 ∼139 nM;K D2 ∼23 nM)( Ta ble2 ). t-PAa nd t-PA:PAI-2 alsob oundt oL RP and VLDLR.H owever,these dataw ereb est fit by ao ne-binding site modelwitht-PAand t-PA:PAI-2 binding with very similar moderateaffinities to LRP(K D 66-67 nM)and VLDR(K D 124-131 nM). Interestingly, the affinities of t-PAand t-PA:PAI-2 foreachofthese receptorsw as similar to that of the lowera ffinityb inding interaction between t-PA:PAI-1 and LRPo rV LDLR ( Table 2 ). The
Thrombosisand Haemostasis 104.6/2010 ©Schattauer 2010 highera ffinityb inding (K D2 )o ft -PA:PAI-1 to both LRPa nd VLDLR was duetoasubstantial(100-to 16-fold, respectively)decrease in the dissociation rate constant, indicating much slower dissociation of the complex. The affinityofb inding of t-PAand t-PA:PAI complexest oL RP wasg enerally highert hant hato btained with VLDLR (Table 2) . To our knowledge, there is no previouslyp ublishedd ata describingt he binding of t-PA:PAI-2 to LRPand VLDLR butthe affinities reported here forthe binding of t-PAand t-PA:PAI-1 to LRPare comparable to thoseobtainedby othersusingSPR (43) .
Discussion
Theresultspresented here showthatboth PAI-2 and PAI-1 inhibit the enzymatica ctivityo fP BM cell surfaceb oundt -PAa nd that t-PA:PAI complexesformedatthe cell surfaceare subsequentlyendocytosed, predominantlyvia an LDLR dependent pathway.However,the formation of aserpin-proteasecomplexbetween t-PAand PAI-1, butnot PAI-2, acceleratest-PAendocytosis. Thedifferences in endocytosis of these ligands maybeexplainedbythe kineticdata obtainedfor the binding of t-PAand t-PA:PAI to LRPand VLDLR usingSPR.The formation of complexesbetween PAI-1 and either t-PA or u-PAare thought to causeaconformational changewithin PAI-1 resultinginitexposingahighaffinitybinding sitefor LRP (32, 41) or potentiallyVLDLR,whichc ontributes directly to the enhanced endocytosis of t-PA:PAI-1 or u-PA:PAI-1 complexes from the cell surface. Both LRP (3, 38) and VLDLR (3, 37) playapivotal role in the rapidc learance of surfaceb oundu -PA:PAI-1 and u-PA:PAI-2 complexes. Like PAI-1, PAI-2 has beenshown to accelerate u-PA internalisation duetoanincreased affinityofu-PA:PAI-2 forLRP and VLDLR compared to u-PAa lone (38) . It is possiblet hat formation of the u-PA:PAI-2 complexresultsinaconformational changew ithin u-PAa sP AI-2 does not bind to eitherL RP or VLDLR (36) (37) . Importantly, t-PAa lone andt -PA:PAI-2 show identicalone-sitebinding affinities forLRP and VLDLR,suggestingthatcomplexformation does not alter the binding interaction of t-PAt oLRP or VLDLR.Furthermore, especiallyi nr egardst o VLDLR binding,the similarK D valuesobtainedfor the loweraffinitybinding interactionsoft-PA:PAI-1 compared to thoseobserved fort-PAort-PA:PAI-2 (Table 2 ) suggests thatnofunctional con- formational changeoccurswithin the t-PAmolecule upon complexformation.Therefore it is likely that the differencesinK D values forLRP and VLDLR observed between t-PA:PAI-1 and t-PAor t-PA:PAI-2 arerelated to exposure of the high affinitycryptic bindingsitewithin PAI-1. Of note,comparison of the binding affinities of t-PAand t-PA:PAI forLRP and VLDLR reveals apreference of these ligands forLRP ( Ta ble3). In contrast,u-PAand u-PA:PAI appear to bind with higher affinities to VLDLR compared to LRP (Table 3) . However, the significanceofthese differencesisunclear at thisstage. Interestingly, RAPi nhibited the direct binding of t-PAt ot he PBMcellsurface by about30%.This observation is similar to that reported by Mulder et al. (39) , wherepre-treatment with RAPresulted in a25% reduction of t-PAbinding to the cell surfaceofHUVECs.The identities of other receptorsresponsiblefor the remainingproportion of t-PAbinding arepotentially numerous,ofwhich p36may partially contribute to total t-PAbinding on these cells, as previously published (42) . Theabsenceoft he mannoser eceptor on our freshlyisolated PBMs cellswas not surprisingasitisindicative of amonocyteversusadifferentiated macrophage phenotype (12) . That fucoidin inhibited the clearanceoft -PAand t-PA:PAI complexesfromthe surfaceofP BMs by about10-20%,suggests thatotherscavenger receptorspresent on PBMs playaminorrole in the binding and subsequentendocytosis of these ligands.
Thet raditional role of t-PAi nf ibrinolysis and of PAI-1 as a regulator of t-PAiswellcharacterised. However, in recent yearsit hasbecomeincreasinglyclear that t-PAisnot restricted to maintaining homeostasis of coagulation and fibrinolysis withinthe vasculature. t-PA hasb eenf oundt oi nducem atrixm etalloproteinase-9geneexpressioninrat kidneyinterstitialfibroblastand promoteactivation of murine myofibroblasts (43), controlpermeabilityoft he blood brainbarrier (44) , facilitatemigration of monocytesacrossthe blood-brain barrier into the centralnervous system(45) and coordinatemacrophage migration under inflammatory conditions ( 46) . Interestingly, thisd iversityi nf unction appearstobedependent on t-PAinteraction with LRP, whichinitiates activation of signalling cascades,whilst not always requiringt he proteolyticactivityoft-PA. Expression of both t-PAand PAI-2 by monocytes, macrophages and myeloid progenitorswithin normal bone marrow (5), suggests aphysiologicalrole forP AI-2 as an inhibitor of t-PAa ssociatedw ithd erivatives of the myeloid stem cells. Thed ifferential endocytosis mechanismsi dentifiedi no ur work suggest thatwhile PAI-1 and PAI-2 both function similarly in the controlofplasmingeneration by t-PAatthe cell surface, they mayhave opposingeffects on the non-classicalrolesoft -PAand activation of signalling cascades viaLRP or indeed VLDLR.
The molecular mechanismsand biologicalsignificanceofarole forVLDLR in the endocytosis of t-PAort-PA:PAI complexesare poorlyunderstood.VLDLR is not found withinthe liver; however, it is expressedatvariedlevelsthroughout the body(3). Therefore, whilst the SPR analyses indicatedthatt-PAand t-PA:PAI bound to
What is knownabout this topic?
• Peripheralbloodmonocytes and macrophages express andsecrete t-PA and u-PAwhich resultsincellsurfaceplasmingeneration.
• Plasmina ctivation at the cells urfaceo fm onocytes and macrophages contributes to awiderange of downstreamphysiological functions.Early research focusedonthe role of theu-PAinmonocyte biology;h owever,i ti sn ow knownt hat t-PAf acilitates migration of myeloid cells fromt he bone marrow, monocytes and peritoneal macrophages in responsetoinflammatory mediators.
• Recent research hasshownthe importance of t-PAwithin thecentral nervous system, where is also knownt oa ctivate microglia (macrophageo ft he CNS) andf acilitym igration of monocytes across theblood-brainbarrier.
• TheSERPINs PAI-1and PAI-2are knowntoinhibit t-PA.
• Themainphysiologicalinhibitor of t-PAisPAI-1; however,PAI-2is also knownt of ormi nhibitoryc omplexesw itht his PA.Research has focused on therole of PAI-1incontrolling t-PA-facilitated plasming enerationa nd thep hysiologicalc onsequences associated with this endocytosiso ft his serpin:protease complex, viaL RP. However,withrespect to myeloid biology,previouspublications in this area of research havebeen inconsistentand incomplete.
What doesthispaper add?
• This paper clarifies the roleofbothPAI-1and PAI-2inthe endocytosisoft-PAfromthe cell surfaceofperipheral blood monocytes.
• Botht-PA:PAI-1and t-PA:PAI-2complexesare cleared fromthe cell surfacevia thelow-densitylipoproteinreceptor familymembers.
• Surface plasmon resonancea nalysisi ndicates that the very-lowdensity-lipoproteinreceptor mayalsofacilitateendocytosisoft-PA and t-PA:PAI complexes. All previous research has focused on LRP as the endocyticreceptor for t-PA or t-PA:PAI-1complexes.
• WhilstbothPAI-1and PAI-2are able to inhibit t-PAatthe cell surfacethe rate of clearanceofthese ligands is markedlydifferent.
• This data provides some novel mechanistic insight intodifferential endocytosiso ft -PA, t-PA:PAI-1t -PA:PAI-2, whichs uggestst hat while PAI-1and PAI-2bothfunction similarlyinthe controlofcellularplasmingenerationbyt-PA, they may havedisparateeffects on thefunctional consequences of t-PAendocytosis.
Leeetal. t-PAand t-PA:PAI-1 versus t-PA:PAI-2 interactions with LRP andVLDLR
VLDLR with approximatelytwo-fold lowerbinding affinities than to LRP(Ta ble2), it is plausiblethatVLDLR mayalsoplayanimportant role in localc learance of t-PAa nd t-PA:PAI complexes. This could be through removalofproteolytic activity and/orpotentiation of down stream signalling cascades throughcellsurface interactionswiththese ligands. Overall, we have shown that the serpinsPAI-1 andPAI-2 areefficientinhibitorsofcellassociatedt-PAand that these protease:serpinc omplexesa re indeed endocytosed, predominantlyv ia an LDLR-dependent pathway on PBMs. Identification of potential downstream consequences associatedwiththe differential endocytosis patternsobserved in thisstudy,may offer newinsight into the role of these cellsini nflammatory environments and the prevalenceofmyeloid diseases.
